Anna et al, 1 High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris François Anna 1 *, Sophie Goyard 2,3 *, Ana Ines Lalanne 4,5 *, Fabien Nevo 1,6 , Marion Gransagne 7 , Philippe Souque 6 , Delphine Louis 4,5 , Véronique Gillon 8 , Isabelle Turbiez 8 , François-Clément Bidard 5,9,10 , Aline Gobillion 11 , Alexia Savignoni 11 , Maude Guillot-Delost 5,12 , François Dejardin 13 , Evelyne Dufour 13 , Stéphane Petres 13 , Odile Richard-Le Goff 14 , Zaineb Choucha 7 , Olivier Helynck 15 , Yves L. Janin 15 , Nicolas Escriou 7 , Pierre Charneau 1,6 , Franck Perez 16 , Thierry Rose 2,3 **, Olivier Lantz 4,5,12 ** Author affiliations 1. Theravectys, Paris, 75015, France 2. Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, 75015, France 3. INSERM 1221, Institut Pasteur, Paris, 75015, France 4. Laboratoire d'Immunologie Clinique, Institut Curie, Paris, 75005, France. 5. Centre d'Investigation Clinique en Biothérapie, Institut Curie (CIC-BT1428), Paris, 75005, France 6. Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, 75015, France 7. Innovation Laboratory: Vaccines, Institut Pasteur, Paris, 75015, France 8. Direction of the Clinical Research, Institut Curie, Paris, 75005, France. 9. Medical Oncology Department, Institut Curie, Paris, 75005, France 10. UVSQ, Paris-Saclay University, Saint-Cloud, 92210, France 11. Biometry, Institut Curie, Paris, 75005, France 12. INSERM U932, PSL University, Institut Curie, Paris, 75005, France 13. Production and Purification of Recombinant Proteins Technological Platform, Paris, 75015, France 14. Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, 75015, France 15. Unit of Chemistry and Biocatalysis, Institut Pasteur, UMR 3523 CNRS, Paris, 75015, France 16. Unit of Cell Biology and Cancer, Institut Curie, Paris, 75005, France * These authors contributed equally to this work. ** Senior corresponding authors. TR (rose@pasteur.fr; ORCID ID 0000-0001-8863-0207), OL (olivier.lantz@curie.fr; ORCID, 0000-0003- 3161-7719) Short title Seroprevalence and immune response to SARS-CoV-2 infection in Paris Key words Coronavirus; COVID-19; SARS-CoV-2; ELISA; serology; neutralization; pseudo-types; LuLISA; Bioluminescence All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.10.25.20219030 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.